Aprameya Engineering Ltd IPO Timeline

Aprameya Engineering Ltd IPO opens on 25-Jul-2024, and closes on 29-Jul-2024. The Aprameya Engineering Ltd IPO bid date is from 25-Jul-2024 to 29-Jul-2024. The Cut-off time for UPI Mandate confirmation is 12 P.M. on the next day of issue closing day.

Event Date
Aprameya Engineering Ltd IPO Opening Date 25-Jul-2024
Aprameya Engineering Ltd IPO Closing Date 29-Jul-2024
Basis of Allotment 30-Jul-2024
Initiation of Refunds 31-Jul-2024
Credit of Shares to Demat 31-Jul-2024
Aprameya Engineering Ltd IPO Listing Date 01-Aug-2024

Aprameya Engineering Ltd IPO Lot Size

Aprameya Engineering Ltd IPO lot size is 2000 shares. A retail-individual investor can apply for up to 1 lots (2000 shares or 116000).

Application Lots Shares Amount
Minimum 1 2000 ₹116000
Maximum 1 2000 ₹116000

Aprameya Engineering Ltd IPO Details

Aprameya Engineering Ltd IPO Date 25-Jul-2024 to 29-Jul-2024
Aprameya Engineering Ltd IPO Face Value Shares of ₹10 per share
Aprameya Engineering Ltd IPO Price ₹56 to ₹58 per share
Aprameya Engineering Ltd IPO Lot Size 2000
Issue Size Shares of ₹10 (aggregating up to ₹29.23 Cr)
Fresh Issue Shares of ₹10 (aggregating up to ₹29.23 Cr)
Offer for Sale -
Issue Type Book Building - SME
Listing At NSE - SME
QIB Shares Offered -
Retail Shares Offered -
NII (HNI) Shares Offered -
Company Promoters Saurabh Kishorebhai Bhatt, Chetan Mohan Joshi, Archana Chetan Joshi.

Objects of the Issue

The company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

  • 1 To meet incremental working capital requirements
  • 2 General corporate purposes

Company Financials

Aprameya Engineering Ltd Financial Information (Restated)

Period Ended Total Assets Total Revenue Profit After Tax
03-2024 75.60 65.62 3.46
03-2023 61.89 78.33 5.37
03-2022 48.63 35.04 7.46
Amount in ₹ Crore
  • Rapid growth in the business with focus on setting up of healthcare infrastructure.
  • Track record of execution capabilities of setting up ICUs NICUs PICUs as well as Operation Theatre.
  • Firm arrangement with many medical equipment suppliers and manufacturers.
  • Wide customer base including many Private and Government Hospital /Medical college.
  • Experienced Promoters with technical team having domain knowledge.
  • Asset light scalable business model.
  • Loss of any of its key customers or significant reduction in demand from, its significant customers may materially and adversely affect its business and financial performance.
  • Many of its work orders are awarded primarily through competitive bidding processes. There is no assurance that future contracts will be awarded to it by these customers. Also, the tenders floated by the government agencies have terms that are suitable to such agencies. This may result in an adverse effect on its business growth, financial and results of operations.
  • The company depends significantly on customers and their spending in the healthcare infrastructure industry and any decline in the spending on healthcare infrastructure in India, could adversely affect its business and profitability.
  • Its Order Book may not be representative of its future results and its actual income may be significantly less than the estimates reflected in its Order Book, which could adversely affect its results of operations.
  • The company has diversified into the business related to installation, set up & maintenance of ICU, NICU, PICU and Operation Theatre in the recent past and are subject to risks associated with new offerings and may not successfully implement its new business models.
  • The company faces risks relating to sourcing medical equipments from third parties. Failure of such third parties to meet their obligations could adversely affect its business and results of operations.
  • Any delays in the completion of its current and future projects could lead to termination of work orders or cost overruns, which could have an adverse effect on its cash flows, business, results of operations and financial condition.
  • Certain of its properties, including the Registered Office, Branch Office and Warehouse are leased from its promoters, directors and third parties. There can be no assurance that these lease agreements will be renewed upon termination or that its will be able to obtain other premises on lease on same or similar commercial terms.
  • The company is required to obtain, renew or maintain certain statutory and regulatory permits and approvals required to operate its business and if its fail to do so in a timely manner or at all and its business, financial conditions, results of operations, and cash flows may be adversely affected.
  • The company derives a significant portion of its revenue from the state of Rajasthan and any adverse developments in these market could adversely affect its business.
  • Its operates in a highly competitive industry and increased competition may lead to a reduction in its revenues, reduced profit margins or a loss of market share.
  • The company depends on the skills and experience of its senior management and other key personnel with technical expertise and the loss of any of those personnel or the inability to attract and retain qualified personnel could materially and adversely affect its business and operations.
  • If the company fails to undertake maintenance works or if there is any deficiency in the services regarding the installation work undertaken by it, the company may be subject to penalties or even termination of its contracts, which may have a material adverse effect on its reputation, business, financial condition, results of operations and cash flows.
  • Its results of operations are likely to vary from year to year and be unpredictable, which could cause the market price of the Equity Shares to decline.
  • The company is subject to strict quality requirements and any failure by it to comply with quality standards may lead to cancellation of existing and future orders, warranty claims and other disputes and claims.
  • Some of its Group Entities operate in the same line of business as it, which may lead to competition with such Group Entities.
  • Its sometimes relies on independent consultants to prepare the design for its turnkey projects and failure on part of these independent consultants may have an adverse effect on its business.
  • Any failures of a consortium partner to perform its obligations could impose additional financial and performance obligations resulting in reduced profits and may have an adverse effect on its business, results of operations and financial condition.
  • Its Promoters have provided guarantees for loans availed by it, and in the event the same is enforced against its Promoters, it could adversely affect its Promoters' ability to manage the affairs of the Company.
  • The Company and its Directors are involved in certain legal proceedings, and an adverse outcome in any such proceedings may adversely affect its business, financial condition and growth prospects.
  • The company is dependent on third party transporters for the delivery of medical equipment and are exposed to the risk of disruption in their operations or a decrease in the quality of their services.
  • Its business is working capital intensive. If the company experience insufficient cash flows from its operations or are unable to borrow to meet its working capital requirements, it may materially and adversely affect its business and results of operations.
  • Unsecured loans taken by the Company may be recalled on demand.
  • Its Statutory Auditors have included certain matter in their audit reports on the Financial Statements in recent fiscal.
  • The company has entered into related party transactions in the past with its Promoters, relatives of the company Promoters, Directors, and enterprises over which its Directors have a significant influence. Any future transactions with related parties may potentially involve conflicts of interest.
  • The objects of the Issue have not been appraised by any bank or financial institution and the company has not entered into definitive agreements in relation to all of its objects of the Issue. Consequently, any increase in the actual deployment of funds may cause an additional burden on its finance plans.
  • The company is susceptible to risks relating to compliance with various labour, workplace and related laws.
  • The company has incurred indebtedness, and an inability to comply with repayment and other covenants in its financing agreements could adversely affect the company's business and financial condition.
  • Its insurance coverage may not be adequate to protect the company against all material risks.
  • Its contingent liabilities could adversely affect the company financial condition if they materialize.
  • Its net cash flows from operating and investing activities have been negative in some years in the past. Any negative cash flow in the future may affect its liquidity and financial condition.
  • Any variation in the utilization of the Net Proceeds as disclosed in this Red Herring Prospectus shall be subject to certain compliance requirements, including prior approval of the shareholders of the Company.
  • There are other interests of its Promoters and the company Directors in the Company, other than normal remuneration or benefits or reimbursement of expenses incurred.
  • Its Promoters will continue to retain certain influence over the Company after completion of the Issue, which will allow them to influence the outcome of matters submitted for approval of its Shareholders.
  • Fraud, theft, employee negligence or similar incidents may adversely affect its results of operations and financial condition.
  • The company is subject to the risk of failures of, or a material weakness in, its internal control systems.
  • The funding requirements and proposed deployment of the Net Proceeds are based on management's estimates and may be subject to change based on various factors, some of which are beyond its control.
  • The company has not independently verified certain data in this Red Herring Prospectus.
  • The company has issued Equity Shares at prices that may be lower than the Issue Price in past.
  • Significant differences exist between Ind AS and other accounting principles, such as Indian GAAP, U.S. GAAP and IFRS, which investors may be more familiar with and may consider material to their assessment of its financial condition which may be material to investors' assessments of its financial condition, result of operations and cash flows.
  • Any Penalty or demand raise by statutory authorities in future will affect its financial position of the Company.
  • Certain of its investments may be subject to market risk and the company has not made any provisions for a decline of the value of such investments.
  • There is no monitoring agency appointed by the Company to monitor the utilization of the Issue proceeds.
  • The company cannot assure payment of dividends on the Equity Shares in the future.
  • Rights of shareholders under Indian laws may be more limited than under the laws of other jurisdictions.
  • The trading volume and market price of the Equity Shares may be volatile following the Issue.
  • The Issue Price of the Equity Shares may not be indicative of the market price of the Equity Shares after the Issue.
  • Investors may be subject to Indian taxes arising out of income arising on the sale of the Equity Shares.
  • Any future issuance of Equity Shares, or convertible securities or other equity linked instruments by it may dilute your shareholding and sale of Equity Shares by the Promoters or members of its Promoter Group may adversely affect the trading price of the Equity Shares.
  • QIBs and Non-Institutional Investors are not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after the submission of their Bid, and Retail Individual Investors are not permitted to withdraw their Bids after closure of the Bid/ Issue Closing Date.
  • The requirements of being a publicly listed company may strain its resources.
  • Foreign investors are subject to foreign investment restrictions under Indian laws which limit its ability to attract foreign investors, which may adversely affect the market price of the Equity Shares.
  • Expanding its geographical footprint.
  • Continue to enhance its core strengths and execution capability.
  • Intend to expand in-house capabilities in service & maintenance.
  • Strengthen and establish relationships with hospitals and Medical colleges.

Aprameya Engineering Ltd IPO Promoter Holding

Pre Issue Share Holding 99.44%
Post Issue Share Holding 73.12%

Aprameya Engineering Ltd IPO Subscription Status (Bidding Detail)

The Aprameya Engineering Ltd IPO is subscribed 48 times on Jul 29, 2024 05:00:00 PM. The public issue subscribed - times in the retail category, - times in the QIB category, and - times in the NII category. Check Day by Day Subscription Details (Live Status)

Category QIB NII Retail Employee Total
Subscription (times) - - - - 48

Aprameya Engineering Ltd IPO Prospectus

Aprameya Engineering Ltd IPO Listing Date

Listing Date 01 Aug 24
BSE Script 77825
NSE Symbol APRAMEYA
Listing In NSE - SME
ISIN INE0LQG01010
IPO Price ₹58
Face Value ₹10

Aprameya Engineering Ltd IPO Registrar

Link Intime India Pvt Ltd

Phone: +91-022-49186200
Email: aprameya.ipo@linkintime.co.in;
Website: www.linkintime.co.in

Aprameya Engineering Ltd IPO Lead Manager(s)

  1. Hem Securities Ltd

FAQs on Aprameya Engineering Ltd IPO

Aprameya Engineering Ltd IPO, which opens for subscription from 25-Jul-2024 to 29-Jul-2024 has an issue size of ₹29.23 crore. The issue type is book building issue.

In case of pre-apply, your IPO order will be placed on the Exchange as soon as the official bidding for Aprameya Engineering Ltd IPO begins. You will receive a UPI request within 24 hours after the bidding period opens.

Aprameya Engineering Ltd IPO Opens for subscription from 25-Jul-2024 to 29-Jul-2024.

The lot size of Aprameya Engineering Ltd is 2000 shares. Retail investors can subscribe to minimum 1 lot and maximum 1 lots. The minimum and maximum application value is ₹116000 and ₹116000 respectively.

Allotment date for Aprameya Engineering Ltd is 30-Jul-2024 and refund of application amount (in case allotment is not received) will begin from 31-Jul-2024. If your allotment goes through, then shares will be credited in your Demat account by 31-Jul-2024.

The registrar for Aprameya Engineering Ltd IPO is Link Intime India Pvt Ltd. You can check your IPO allotment status on the registrar's website.

The shares of Aprameya Engineering Ltd are proposed to be listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Power your investments with our smart trading platforms

mobilefooterimg
  • app_download_icon_img
    10 million+
    App downloads
  • 1_Click_icon_img
    1-Click
    Order Placement
  • higherreturns_icon_img
    2,203 Crore+
    Average Daily Turnover
Download App
App_Download_QRCode